Skip to main content
. Author manuscript; available in PMC: 2023 Aug 11.
Published in final edited form as: Gastrointest Disord (Basel). 2018 Oct 18;1(1):75–105. doi: 10.3390/gidisord1010007

Figure 3.

Figure 3.

Biologics regarding therapeutic targets (black: showed benefits; violet: no benefits). APC, antigen presenting cell; IEC, intestinal epithelial cell; TNF, tumor necrosis factor; MHC, major histocompatibility complex; TCR, T cell receptor; JAK, Janus kinase; TGF, transforming growth factor; IL, interleukin; MAdCAM, mucosal vascular addressing cell adhesion molecule. Adapted with permission from “Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies” by Kim and Cheon, Immune Netw. 2017, 17, 25–40 [46].